• Something wrong with this record ?

Positive Attributes of Anti-TERT CD4 T-Helper Type 1 Immune Responses in Melanoma

E. Nagore, A. Virós, R. Kumar

. 2022 ; 142 (2) : 279-281. [pub] 20211016

Language English Country United States

Document type Journal Article, Comment

Persistent link   https://www.medvik.cz/link/bmc22011171

Grant support
110078/Z/15/Z Wellcome Trust - United Kingdom

Nardin et al's (2021) study on melanoma reports anti-TERT CD4 T helper type (Th) 1 responses in more than half of patients. Besides indicating a trend for improved survival, increased anti-TERT CD4 Th1 responses predicted better outcomes for patients treated with immune checkpoint inhibitors. Thus, harnessing systemic anti-TERT CD4 Th1 responses together with tumor-specific elevation of telomerase can potentially open new avenues for biomarkers and treatment in melanoma.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22011171
003      
CZ-PrNML
005      
20220506130030.0
007      
ta
008      
220425s2022 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jid.2021.09.005 $2 doi
035    __
$a (PubMed)34666894
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Nagore, Eduardo $u Department of Dermatology, Instituto Valenciano de Oncologia, Valencia, Spain
245    10
$a Positive Attributes of Anti-TERT CD4 T-Helper Type 1 Immune Responses in Melanoma / $c E. Nagore, A. Virós, R. Kumar
520    9_
$a Nardin et al's (2021) study on melanoma reports anti-TERT CD4 T helper type (Th) 1 responses in more than half of patients. Besides indicating a trend for improved survival, increased anti-TERT CD4 Th1 responses predicted better outcomes for patients treated with immune checkpoint inhibitors. Thus, harnessing systemic anti-TERT CD4 Th1 responses together with tumor-specific elevation of telomerase can potentially open new avenues for biomarkers and treatment in melanoma.
650    _2
$a lidé $7 D006801
650    _2
$a imunita $7 D007109
650    _2
$a imunoterapie $7 D007167
650    12
$a melanom $x farmakoterapie $7 D008545
650    12
$a telomerasa $7 D019098
650    _2
$a Th1 buňky $7 D018417
655    _2
$a časopisecké články $7 D016428
655    _2
$a komentáře $7 D016420
700    1_
$a Virós, Amaya $u Cancer Research UK Manchester Institute, The University of Manchester, Manchester, United Kingdom
700    1_
$a Kumar, Rajiv $u Division of Functional Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany; Institute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany; Department of Molecular Biology of Cancer, Institute of Experimental Medicine CAS, Czech Academy of Sciences, Prague, Czech Republic. Electronic address: r.kumar@dkfz.de
773    0_
$w MED00002756 $t The Journal of investigative dermatology $x 1523-1747 $g Roč. 142, č. 2 (2022), s. 279-281
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34666894 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506130022 $b ABA008
999    __
$a ok $b bmc $g 1788992 $s 1162369
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 142 $c 2 $d 279-281 $e 20211016 $i 1523-1747 $m Journal of investigative dermatology $n J Invest Dermatol $x MED00002756
GRA    __
$a 110078/Z/15/Z $p Wellcome Trust $2 United Kingdom
LZP    __
$a Pubmed-20220425
Back

Find record

Citation metrics

Archiving options